Fig. 3From: Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET studyImprovements in BCVA from baseline to end of the study. BCVA best corrected visual acuity, ITT intent-to-treat population, PP per-protocol populationBack to article page